methyl 3-(N,4-dimethylphenylsulfonamido)-4-methylbenzoate | 1309477-83-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3-(N,4-dimethylphenylsulfonamido)-4-methylbenzoate
• 英文别名: Methyl 4-methyl-3-[methyl-(4-methylphenyl)sulfonylamino]benzoate
• CAS: 1309477-83-5
• 化学式: C₁₇H₁₉NO₄S
• 分子量: 333.408
• InChiKey: JPIZSBPXRHIUHB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-氨基-4-甲基苯甲酸甲酯 、 对甲苯磺酰氯 在 吡啶 、 sodium hydride 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.08h， 生成 methyl 3-(N,4-dimethylphenylsulfonamido)-4-methylbenzoate
  参考文献：
  名称：

  Toluidinesulfonamide Hypoxia-Induced Factor 1 Inhibitors: Alleviating Drug–Drug Interactions through Use of PubChem Data and Comparative Molecular Field Analysis Guided Synthesis

  摘要：

  Inhibitors of hypoxia-inducible factor 1 (HIF-1) represent promising anticancer therapeutics. We have identified a series of potent toluidinesulfonamide HIF-1 inhibitors. However, the series was threatened by a potential liability to inhibit CYP2C9 which could cause dangerous drug drug interactions when being coadministered with other drugs. We used structure activity data from the Pub Chem database to develop a topomer CoMFA model that guided the design of novel sulfonamides with high selectivity for HIF-1 over CYP2C9 inhibition.

  DOI：

  10.1021/jm200272h

文献信息

• Toluidinesulfonamide Hypoxia-Induced Factor 1 Inhibitors: Alleviating Drug–Drug Interactions through Use of PubChem Data and Comparative Molecular Field Analysis Guided Synthesis
  作者：Bernd Wendt、Marcel Mülbaier、Sabine Wawro、Christoph Schultes、Jorge Alonso、Bernd Janssen、Joe Lewis

  DOI：10.1021/jm200272h

  日期：2011.6.9

  Inhibitors of hypoxia-inducible factor 1 (HIF-1) represent promising anticancer therapeutics. We have identified a series of potent toluidinesulfonamide HIF-1 inhibitors. However, the series was threatened by a potential liability to inhibit CYP2C9 which could cause dangerous drug drug interactions when being coadministered with other drugs. We used structure activity data from the Pub Chem database to develop a topomer CoMFA model that guided the design of novel sulfonamides with high selectivity for HIF-1 over CYP2C9 inhibition.